Showing posts with label Covid-19. Show all posts
Showing posts with label Covid-19. Show all posts
Sunday, August 29, 2021

Drug names: brand name, proprietary name, trade name, generic name, and sponsor's drug code

›
Every Saturday, my favorite radio show is " Wait Wait... Don't Tell Me! | WUNC ". In yesterday's episode, the host made fu...
6 comments:
Monday, January 11, 2021

Single Imputation Methods for Missing Data: LOCF, BOCF, LRCF (Last Rank Carried Forward), and NOCB (Next Observation Carried Backward)

›
The missing data is always an issue when analyzing the data from clinical trials. The missing data handling has been moved toward the model-...
Thursday, October 15, 2020

The fate of confirmatory clinical trials for Remdesivir for treatment of COVID-19

›
Remdesivir, as the first highly touted drug to treat COVID-19 patients, has now been approved for emergency use authorization in several cou...
Tuesday, October 06, 2020

Covid-19 Vaccine: Is 50% Vaccine Efficacy (VE) Too Low?

›
Ever since FDA issued its guidance “ Development and Licensure of Vaccines to Prevent COVID-19 ,” to help facilitate timely development of s...
1 comment:
Thursday, August 27, 2020

How to interpret the risk ratio? - A controversy related to FDA's EUA announcement of convalescent plasma in treatment of Covid-19

›
This past Sunday, FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievem...
2 comments:
Sunday, July 26, 2020

Blinding and Masking Issue in Covid-19 Vaccine Clinical Trials

›
Clinical trials for Covid-19 vaccine development are moving into the critical late phase stage. The front runners right now are Moderna (in ...
7 comments: